Veloxis prepares for US launch
While Veloxis is trying to keep down R&D costs, the Danish biotech is instead using the funds to build up a marketing apparatus in the US for a drug that recently won EU approval.
BY LEONORA BECK
The public, Danish biotech company Veloxis, which published its latest financial report last week, emerged from its second quarter with a noticeable deficit on the bottom line.
Allerede abonnent?Log ind her
Læs hele artiklen
Få adgang i 14 dage for 0 kr. Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.
Med din prøveperiode får du:
Få fuld adgang til dig og dine kollegaer
Start et gratis virksomhedsprøveabonnementRelaterede artikler
Veloxis gears up for US launch
For abonnenter
